|
Congestive heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We defined cardiovascular death and hospitalization for HF as adverse events and evaluated the prognostic value of the BNP levels in each group.
|
28941144 |
2018 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Elevated circulating plasma NP levels correlate with the severity of heart failure and particularly BNP and the pro-peptide, NT-proBNP have been established as biomarkers for the diagnosis of heart failure as well as prognostic markers for cardiovascular risk.
|
29411335 |
2018 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The developed LFIA for BNP could rapidly rule out HF with the naked eye, offering tremendous potential for POC test and personalized medicine.
|
28670119 |
2017 |
|
Congestive heart failure
|
0.600 |
Therapeutic
|
disease |
CTD_human |
Nesiritide: past, present, and future.
|
16333235 |
2005 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Change of BNP between admission and discharge after ST-elevation myocardial infarction (Killip I) improves risk prediction of heart failure, death, and recurrent myocardial infarction compared to single isolated measurement in addition to the GRACE score.
|
29359586 |
2019 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Daily home BNP monitoring in heart failure for prediction of impending clinical deterioration: results from the HOME HF study.
|
29314505 |
2018 |
|
Congestive heart failure
|
0.600 |
Therapeutic
|
disease |
CTD_human |
The effects of atorvastatin (10 mg) on systemic inflammation in heart failure.
|
16360360 |
2005 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
Nesiritide: past, present, and future.
|
16333235 |
2005 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
TLR2 and TLR3 expression as a biomarker for the risk of doxorubicin-induced heart failure.
|
29959987 |
2018 |
|
Congestive heart failure
|
0.600 |
Therapeutic
|
disease |
CTD_human |
TLR2 and TLR3 expression as a biomarker for the risk of doxorubicin-induced heart failure.
|
29959987 |
2018 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
There was a significant step-up of the plasma BNP-LI level in the coronary sinus (CS) compared with that in the aortic root (Ao) and the difference between these BNP-LI levels, delta(CS-Ao)BNP, also increased with the severity of CHF.
|
1849149 |
1991 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the case of BNP-32, the sensor developed has a linear response from 1 pg mL<sup>-1</sup> to 1 μg mL<sup>-1</sup> in serum; for cTnI, linearity is observed from 1 pg mL<sup>-1</sup> to 10 ng mL<sup>-1</sup> as demanded for early-stage diagnosis of heart failure.
|
30320285 |
2018 |
|
Congestive heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Brain natriuretic peptide (BNP) gene expression accompanies cardiac hypertrophy and heart failure.
|
11230322 |
2001 |
|
Congestive heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The linear correlation between the CIB1 and pro-BNP levels in observation group 1 was observed, and the diagnostic value of CIB1 and pro-BNP levels for chronic stable ischemic heart failure were analyzed using the receiver operating characteristic (ROC) curve.
|
29028109 |
2017 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Natriuretic peptides (BNP and NT-proBNP) are largely used for monitoring patients with cardiac failure but are highly dependent on glomerular filtration rate (GFR).
|
30402040 |
2018 |
|
Congestive heart failure
|
0.600 |
Therapeutic
|
disease |
CTD_human |
Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.
|
11279304 |
2000 |
|
Congestive heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that aerobic exercise training with vascular occlusion can improve exercise capacity and serum BNP levels in patients with chronic heart failure.
|
29575708 |
2018 |
|
Congestive heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
For example, GWAS of NT-proBNP levels not only identified variants in the NNPA-NPPB locus but also substantiated data suggesting that natriuretic peptides in itself are associated with a lower risk of hypertension and HF.
|
29912321 |
2018 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
NT -pro BNP as a Mediator of the Racial Difference in Incident Atrial Fibrillation and Heart Failure.
|
30912456 |
2019 |
|
Congestive heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Other cardiovascular complications seen in GBS patients were Increased pro-BNP(26.04%), raised troponin T levels(3.12%), acute coronary syndrome(2.08%), heart failure(2.08%) and abnormal 2D echo findings(8.33%).
|
31504947 |
2020 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
With the exception of transferred HF patients (n = 22), logistic regression analysis that incorporated the CONUT score and the log BNP, showed that a higher CONUT score (P = 0.019) and higher log BNP (P = 0.009) were predictors of in-hospital death, and the median duration of hospital stay was 20 days.Our results demonstrate the usefulness of CONUT scores as predictors of short-term prognosis in hospitalized HF patients.
|
29479009 |
2018 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We examined the molecular forms of secreted and intracellular BNP in atrial and ventricular myocytes; levels of corin and furin mRNA in atrial and ventricular myocytes; the effect their knockdown on proBNP processing; plasma molecular forms of BNP from rats and humans with and without heart failure; and the impact of the distance between the glycosylation and cleavage sites in wild-type and mutant human proBNP, expressed in rat myocytes transfected with lentiviral vectors.
|
26136529 |
2015 |
|
Congestive heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial) trial randomized patients with HFpEF and either prior hospitalization for HF or elevated natriuretic peptide levels (B-type NP [BNP] ≥100 pg/ml or N-terminal proBNP ≥360 pg/ml) to spironolactone or placebo.
|
28359411 |
2017 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The present study investigated the molecular pathology of atrial and brain natriuretic peptides (ANP and BNP) in the myocardium to evaluate terminal cardiac function in routine forensic casework with particular regard to fatal drug intoxication (n = 18; sedative-hypnotics, n = 10; methamphetamine, n = 8), hypothermia (cold exposure, n = 13), and hyperthermia (heatstroke, n = 10), compared with that in acute ischemic heart disease (AIHD, n = 35) and congestive heart disease (CHD, n = 11) as controls (total n = 87; within 48 h postmortem).
|
22752749 |
2012 |
|
Congestive heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
However, in multivariable regression analysis Cystatin C predicted mortality after the adjustment for baseline renal function, AKI, BNP levels and heart failure risk factors.
|
28756070 |
2017 |